1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 2018, 68(6):394-424.
2. Manna AK, Pathak S, Gayen P, Sarkar DK, Kundu AK: Study of immunohistochemistry in prostatic lesions with special reference to proliferation and invasiveness. Indian Journal of Surgery 2011, 73(2):101-106.
3. Xu Y, Wang Y, Zhou R, Li H, Cheng H, Wang Z, Zhang J: The benign mimickers of prostatic acinar adenocarcinoma. Chinese Journal of Cancer Research 2016, 28(1):72.
4. Ortiz AB, Garcia D, Vicente Y, Palka M, Bellas C, Martin P: Prognostic significance of cyclin D1 protein expression and gene amplification in invasive breast carcinoma. PloS one 2017, 12(11):e0188068.
5. Li Y, Wei J, Xu C, Zhao Z, You T: Prognostic significance of cyclin D1 expression in colorectal cancer: a meta-analysis of observational studies. PloS one 2014, 9(4):e94508.
6. Yang WI, Chung KY, Shin DH, Kim YB: Cyclin D1 protein expression in lung cancer. Yonsei medical journal 1996, 37:142-150.
7. Keum J, Kong G, Yang S, Shin D, Park S, Lee J, Lee J: Cyclin D1 overexpression is an indicator of poor prognosis in resectable non-small cell lung cancer. British journal of cancer 1999, 81(1):127.
8. Pereira R, Ravinal R, Costa RS, Lima M, Tucci S, Muglia V, Dos Reis R, Silva GEB: Cyclin D1 expression in prostate carcinoma. Brazilian Journal of Medical Biological Research 2014, 47(6):515-521.
9. Saeed IE, Weng HY, Mohamed KH, Mohammed SI: Cancer incidence in Khartoum, Sudan: first results from the Cancer Registry, 2009–2010. Cancer medicine 2014, 3(4):1075-1084.
10. Saeed ME, Cao J, Fadul B, Kadioglu O, Khalid HE, Yassin Z, Mustafa SM, Saeed E, Efferth T: A five-year survey of cancer prevalence in Sudan. Anticancer research 2016, 36(1):279-286.
11. Kulhánová I, Bray F, Fadhil I, Al-Zahrani AS, El-Basmy A, Anwar WA, Al-Omari A, Shamseddine A, Znaor A, Soerjomataram I: Profile of cancer in the Eastern Mediterranean region: The need for action. Cancer epidemiology 2017, 47:125-132.
12. Gleason DF: Histologic grading of prostate cancer: a perspective. Human pathology 1992, 23(3):273-279.
13. Nakamura Y, Felizola SJ, Kurotaki Y, Fujishima F, McNamara KM, Suzuki T, Arai Y, Sasano H: Cyclin D1 (CCND1) expression is involved in estrogen receptor beta (ERβ) in human prostate cancer. The Prostate 2013, 73(6):590-595.
14. Aaltomaa S, Eskelinen M, Lipponen P: Expression of cyclin A and D proteins in prostate cancer and their relation to clinopathological variables and patient survival. The Prostate 1999, 38(3):175-182.
15. Wong M, Bierman Y, Pettaway C, Kittles R, Mims M, Jones J, Ittmann M: Comparative analysis of p16 expression among African American and European American prostate cancer patients. The Prostate 2019.
16. Wu X, Scott H, Carlsson SV, Sjoberg DD, Cerundolo L, Lilja H, Prevo R, Rieunier G, Macaulay V, Higgins GS: Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy. The Prostate 2019.
17. Duijvesz D, Rodriguez‐Blanco G, Hoogland AM, Verhoef EI, Dekker LJ, Roobol MJ, van Leenders GJ, Luider TM, Jenster G: Differential tissue expression of extracellular vesicle‐derived proteins in prostate cancer. The Prostate 2019.
18. Krzyzanowska A, Don‐Doncow N, Marginean FE, Gaber A, Watson RW, Hellsten R, Bjartell A: Expression of tSTAT3, pSTAT3727, and pSTAT3 705 in the epithelial cells of hormone‐naïve prostate cancer. The Prostate 2019.
19. Nie L, Pan X, Zhang M, Yin X, Gong J, Chen X, Xu M, Zhou Q, Chen N: The expression profile and heterogeneity analysis of ERG in 633 consecutive prostate cancers from a single center. The Prostate 2019.
20. Zukerberg LR, Yang W-I, Gadd M, Thor AD, Koerner FC, Schmidt EV, Arnold A: Cyclin D1 (PRAD1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene. Modern pathology 1995, 8(5):560-567.
21. Naitoh H, Shibata J, Kawaguchi A, Kodama M, Hattori T: Overexpression and localization of cyclin D1 mRNA and antigen in esophageal cancer. The American journal of pathology 1995, 146(5):1161.
22. Chen Y, Martinez LA, LaCava M, Coghlan L, Conti CJ: Increased cell growth and tumorigenicity in human prostate LNCaP cells by overexpression to cyclin D1. Oncogene 1998, 16(15):1913.
23. Hashimoto Y, Nakamura N, Kuze T, Abe M, Wakasa H: Intranuclear expression of cyclin D1 protein as a useful prognostic marker for mantle cell lymphoma. Fukushima journal of medical science 1997, 43(2):87-98.
24. Gansauge S, Gansauge F, Ramadani M, Stobbe H, Rau B, Harada N, Beger HG: Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer research 1997, 57(9):1634-1637.
25. Shin K, Kong G, Kim W, Lee T, Woo Y, Lee J: Overexpression of cyclin D1 correlates with early recurrence in superficial bladder cancers. British journal of cancer 1997, 75(12):1788.
26. Gumbiner LM, Gumerlock PH, Mack PC, Chi SG, deVere White RW, Mohler JL, Pretlow TG, Tricoli JV: Overexpression of cyclin D1 is rare in human prostate carcinoma. The Prostate 1999, 38(1):40-45.
27. Bahnassy AA, Zekri A-RN, El-Houssini S, El-Shehaby AM, Mahmoud MR, Abdallah S, El-Serafi M: Cyclin A and cyclin D1 as significant prognostic markers in colorectal cancer patients. BMC gastroenterology 2004, 4(1):22.
28. Dunsmuir W, Gillett C, Meyer L, Young M, Corbishley C, Eeles R, Kirby R: Molecular markers for predicting prostate cancer stage and survival. BJU international 2000, 86(7):869-878.
29. Ozbek E, Mizrak B, Ozbek M, Buyukberber S, Davarci M: Cyclin-D1 protooncogen expression in prostate cancer. Turk J Cancer 2000, 30(30):15-21.
30. Kallakury BV, Sheehan CE, Ambros RA, Fisher HA, Kaufman Jr RP, Ross JS: The prognostic significance of p34cdc2 and cyclin D1 protein expression in prostate adenocarcinoma. Cancer: Interdisciplinary International Journal of the American Cancer Society 1997, 80(4):753-763.
31. Han EKH, Lim JT, Arber N, Rubin MA, Xing WQ, Weinstein IB: Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors. The Prostate 1998, 35(2):95-101.
32. Tsai H, Morais CL, Alshalalfa M, Tan H-L, Haddad Z, Hicks J, Gupta N, Epstein JI, Netto GJ, Isaacs WB: Cyclin D1 loss distinguishes prostatic small-cell carcinoma from most prostatic adenocarcinomas. Clinical Cancer Research 2015, 21(24):5619-5629.
33. Drobnjak M, Osman I, Scher HI, Fazzari M, Cordon-Cardo C: Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clinical Cancer Research 2000, 6(5):1891-1895.
34. Fleischmann A, Rocha C, Saxer‐Sekulic N, Zlobec I, Sauter G, Thalmann GN: High‐level cytoplasmic cyclin D1 expression in lymph node metastases from prostate cancer independently predicts early biochemical failure and death in surgically treated patients. Histopathology 2011, 58(5):781-789.
35. He Y, Franco OE, Jiang M, Williams K, Love HD, Coleman IM, Nelson PS, Hayward SW: Tissue-specific consequences of cyclin D1 overexpression in prostate cancer progression. Cancer research 2007, 67(17):8188-8197.
36. Ding G, Liu J, Feng C, Jiang H, Xu J, Ding Q: Slug regulates Cyclin D1 expression by ubiquitin-proteasome pathway in prostate cancer cells. Panminerva medica 2012, 54(3):219-223.
37. Koontz BF, Tsivian M, Mouraviev V, Sun L, Vujaskovic Z, Moul J, Lee WR: Impact of primary Gleason grade on risk stratification for Gleason score 7 prostate cancers. International Journal of Radiation Oncology* Biology* Physics 2012, 82(1):200-203.
38. Lughezzani G, Gallina A, Larcher A, Briganti A, Capitanio U, Suardi N, Lista G, Abrate A, Sangalli MN, Buffi N: Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer. BJU international 2013, 111(5):723-730.
39. Wilt TJ, Abrahamsson P-A, Crawford ED, Lucia MS, Sakr WA, Schalken J: Prostate cancer: epidemiology and screening. Reviews in urology 2003, 5(Suppl 6):S3.
40. Cookson MS, Fleshner NE, Soloway SM, Fair WR: Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications. The Journal of urology 1997, 157(2):559-562.
41. Kulkarni JN, Valsangkar RS, Jadhav YR, Singh DP: Impact of Gleason pattern up gradation after radical prostatectomy for carcinoma prostate patients with low biopsy score (≤ 6). Journal of cancer research therapeutics 2011, 7(4):459.